托珠单抗与泼尼松在csDMARDs应答不足类风湿关节炎患者中的疗效比较(TOPIRA):一项实用性试验的研究方案
本研究为多中心、研究者发起的开放标签随机实用性试验,计划纳入120例对csDMARDs应答不足的活动性RA患者,1:1随机接受托珠单抗皮下162 mg/周或泼尼松口服10 mg/日联合现有csDMARDs治疗。主要结局为基线至12个月CDAI变化,旨在头对头比较两种策略的疗效与安全性。
要点
- 对csDMARDs应答不足的RA患者,托珠单抗与泼尼松头对头比较尚属首次。
- 主要结局为12个月CDAI变化,同时评估安全性、影像学进展及成本效用。
- 达到临床缓解者将逐步减量,持续高疾病活动度者切换至另一策略组。
核心结论
- 托珠单抗与泼尼松在csDMARDs应答不足的RA患者中孰优孰劣尚不明确,本试验将提供头对头比较证据。
研究设计与样本
- 多中心、研究者发起的开放标签随机实用性试验,计划招募120例符合2010 ACR/EULAR分类标准且CDAI>10、至少1个肿胀关节的RA患者。
- 纳入者需稳定使用csDMARDs≥8周且既往≥2种DMARDs(其中最多一种TNF抑制剂),随机1:1接受托珠单抗皮下162 mg/周或泼尼松口服10 mg/日联合现有csDMARDs。
- 访视点为筛选、基线及第1、2、3、6、9、12个月。
关键数值与推荐
- 主要结局为基线至12个月CDAI变化。
- 临床缓解定义为连续两次3个月访视CDAI≤2.8且肿胀关节≤1,此时研究药物逐步减量。
- 第3个月或之后持续高疾病活动度(任一次访视CDAI>22或连续两次>10)者切换至另一策略组。
- 次要结局包括其他临床应答与生活质量指标、药物留存率、影像学关节损伤进展、功能能力及成本效用。
临床怎么用
- 为临床风湿病实践中csDMARDs应答不足后选择托珠单抗或泼尼松提供直接比较证据。
- 方案包含缓解后减量与高疾病活动度切换策略,贴近临床实际决策路径。
局限性
- 开放标签设计可能引入偏倚。
- 计划样本量120例,检验效能可能限制次要结局比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, predominantly affecting joints, which is initially treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). In RA patients with insufficient response to csDMARDs, the addition of prednisone or tocilizumab, a biological DMARD (bDMARD), to the medication has been shown to be effective in reducing RA symptoms. However, which of these two treatment strategies has superior effectiveness and safety is unknown. METHODS: In this multicenter, investigator-initiated, open-label, randomized, pragmatic trial, we aim to recruit 120 RA patients meeting the 2010 ACR/EULAR classification criteria for RA, with active disease defined as a Clinical Disease Activity Index (CDAI) > 10 and at least one swollen joint of the 28 assessed. Patients must be on stable treatment with csDMARDs for ≥ 8 weeks prior to screening and must have been treated with ≥ 2 DMARDs, of which a maximum of one tumor necrosis factor inhibitor (a class of bDMARDs) is allowed. Previous use of other bDMARDs or targeted synthetic DMARDs is not allowed. Patients will be randomized in a 1:1 ratio to receive either tocilizumab (subcutaneously at 162 mg/week) or prednisone (orally at 10 mg/day) as an addition to their current csDMARD therapy. Study visits will be performed at screening; baseline; and months 1, 2, 3, 6, 9, and 12. Study medication will be tapered in case of clinical remission (CDAI ≤ 2.8 and ≤ 1 swollen joint at two consecutive 3-monthly visits) with careful monitoring of disease activity. In case of persistent high disease activity at or after month 3 (CDAI > 22 at any visit or > 10 at two consecutive visits), patients will switch to the other strategy arm. Primary outcome is a change in CDAI from baseline to 12 months. Secondary outcomes are additional clinical response and quality of life measures, drug retention rate, radiographically detectable progression of joint damage, functional ability, and cost utility. Safety outcomes include tocilizumab-associated adverse events (AEs), glucocorticoid-associated AEs, and serious AEs. DISCUSSION: This will be the first randomized clinical trial comparing addition of oral prednisone or of tocilizumab head to head in RA patients with insufficient response to csDMARD therapy. It will yield important information for clinical rheumatology practice. TRIAL REGISTRATION: This trial was prospectively registered in the Netherlands Trial Register on October 7, 2019 (NL8070). The Netherlands Trial Register contains all items from the World Health Organization Trial Registration Data Set.
引用
- van der Leeuw MS, Welsing PMJ, de Hair MJH, et al. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. Trials. 2020. PMID: 32248829. doi:10.1186/s13063-020-04260-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。